IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
The Prolonged Use of Topiramate for Preventing Migraine Headaches (PROMPT)
This study has been completed.
Sponsor:
Janssen Pharmaceutica N.V., Belgium
Information provided by (Responsible Party):
Janssen Pharmaceutica N.V., Belgium
ClinicalTrials.gov Identifier:
NCT00216619
First received: September 13, 2005
Last updated: July 1, 2014
Last verified: July 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and effectiveness (beyond 6 months) of individualized doses (100 to 200 milligrams) of topiramate for the prevention of migraine headaches over a period of 26 weeks.
| Condition | Intervention | Phase |
|---|---|---|
| Migraine | Drug: Topiramate Drug: Topiramate - Placebo | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention |
Resource links provided by NLM:
Further study details as provided by Janssen Pharmaceutica N.V., Belgium:
Primary Outcome Measures:
- Change in migraine days compared between the topiramate group and placebo group at the last 4 weeks of the open-label phase and the final 4 weeks of the placebo-controlled phase [ Time Frame: Last 4 weeks of Open Label (OL) Phase and Double Blind (DB) Phase ]
Secondary Outcome Measures:
- Patient's Satisfaction [ Time Frame: Visit 6 ]at the end of the OL Phase and at the end of the DB Phase
- Health related quality of life as recorded in patient questionnaires (MIDAS and SF-12) [ Time Frame: Visit 2, Visit 6, Visit 10 ]At the start of the OL Phase; at the end of the of the OL Phase and at the end of the DB Phase
- Health related quality of life as recorded in patient questionnaire (HIT-6) [ Time Frame: Visit 2, Visit 4, Visit 6, Visit 8, Visit 10 ]HIT-6 extra questioned at Week 8 and Week 34
| Enrollment: | 834 |
| Study Start Date: | November 2003 |
| Study Completion Date: | August 2006 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Open Label Phase
Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
|
Drug: Topiramate
topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
|
|
Experimental: Double Blind and Roll Out Phase
the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
|
Drug: Topiramate
topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
Drug: Topiramate - Placebo
the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
|
Detailed Description:
Previous studies have shown that topiramate is effective in preventing migraine headaches. This study will start with a 4-week baseline period in which no treatment is given, followed by a 26-week period in which each patient's dose is adjusted and then kept stable for 4 weeks. The dose will start at 25 milligrams of topiramate per day and will be increased 25 milligrams per day once weekly and then raised to either the target--100 milligrams per day--or the maximum dose that is well tolerated up to 200 milligrams per day. Patients randomized to receive topiramate will remain on that dose. The comparison phase of the study is a 26-week period in which the change in migraine days of patients on topiramate (taking at least 50 milligrams per day) is compared with the change in migraine days for patients on the placebo. Also studied will be the patients' health-related quality of life as assessed by questionnaires filled out at specific visits as well as the patients' views of the safety and tolerability of topiramate. The study hypothesis is that the number of migraine days, periods, and attacks during the last 4 weeks of the double-blind phase, relative to the last 4 weeks of the open-label phase, is reduced more in the topiramate group than the placebo group. During open-label (26-weeks) and double-blind phase (26-weeks), patients receiving topiramate will take 25 milligrams to 100 milligrams daily by mouth; increased by 25 milligrams per day once weekly; dose cannot exceed 200 milligrams per day and must be stable for the last 4 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Established history of migraine for at least one year;
- Migraine meets HIS (International Headache Society) criteria
- An average of at least 4 monthly migraine days during the 3 months preceding trial entry
- Capable of keeping trial records; Exclusion Criteria:
- Patient used migraine prophylactic medication in the month prior to trial entry (flunarizine: 3 months prior to entry)
- Patient had failed (lack of efficacy) more than two adequate previous regimens of migraine prophylactic medications
- Patient had a history of severe drug allergy or hypersensitivity
- Patient overused analgesics, opiates, ergots and/or triptans
- Patient had been using topiramate regularly
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00216619
Show 70 Study Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00216619
Show 70 Study Locations
Sponsors and Collaborators
Janssen Pharmaceutica N.V., Belgium
Investigators
| Study Director: | Janssen Pharmaceutica N.V. Clinical Trial | Janssen Pharmaceutica N.V. |
More Information
Additional Information:
Publications:
| Responsible Party: | Janssen Pharmaceutica N.V., Belgium |
| ClinicalTrials.gov Identifier: | NCT00216619 History of Changes |
| Other Study ID Numbers: |
CR003931 2005-000321-29 ( EudraCT Number ) TOPMAT-MIG-303 ( Other Identifier: Janssen CTMS ID ) |
| Study First Received: | September 13, 2005 |
| Last Updated: | July 1, 2014 |
Keywords provided by Janssen Pharmaceutica N.V., Belgium:
|
chronic migraine Topiramate migraine headache chronic headache |
Additional relevant MeSH terms:
|
Migraine Disorders Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Topiramate Anticonvulsants Neuroprotective Agents Protective Agents Physiological Effects of Drugs Anti-Obesity Agents |
ClinicalTrials.gov processed this record on July 18, 2017